LIF and hepatocellular carcinoma: More importantly, we established the first cytoplasmic LIF inhibitor, CVB‐D, which interacted with LIF at Val145 and showed promising efficacy in HCC in different mouse models, by inducing LIF/p38MAPK/p62‐dependent mitophagy.